VTRSViatris
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−3% a year). Little growth is priced in even as revenue fell 2% a year over three years, potential value, or a value trap.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What VTRS's price assumes
Today's price asks for −2.9% free cash flow growth a year; over the last three years Viatris delivered −3.6%, so the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 9.5%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- −2.9%
Growth the price implies · The price pays for −2.9% free cash flow growth a year for a decade; the business has delivered −3.6% a year over the last three.
- Price / book
- 1.45
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.45
- EV / EBIToperating margin −0.59%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 2.25
- Free cash flow, trailing twelve months
- $1.95B
- Market capitalisation1.15 billion shares, counted Aug 3, 2026
- $20.7B
- 3-year revenue growth
- −1.9%
- 3-year free cash flow growth
- −3.6%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry